Recurrence rate of superficial bladder cancer with intravesical BCG and mitomycin.
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Intravesical mitomycin C (MMC) therapy is used to treat superficial bladder cancer. This study was to establish the intra- and intersubject variabilities in the systemic (plasma) and target site (bladder) exposure to the drug and to identify the factors which contribute to these variabilities. The pharmacokinetics of MMC were studied in 10 patients. Treatment consisted of transurethral tumor re...
متن کاملSystemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer
Intravesical Bacilli Calmette-Guérin (BCG) immunotherapy is a commonly used treatment for superficial bladder cancer. Although the treatment is well tolerated in 95% of cases, life-threatening side effects including BCG sepsis can occur. This report describes the case of an 82-year-old man with a background of lung disease. He developed septic shock and type two respiratory failure after receiv...
متن کاملTherapies in bladder cancer: intravesical mitomycin-C
The use of intravesical therapy for the treatment of superficial bladder cancer aims to reduce morbidity and mortality by eradicating existing disease, preventing tumor recurrence and attempting to halt tumor progression. Mitomycin-C is a commonly used intravesical treatment option for superficial bladder cancer and was used for the first time by Shida and colleagues in 1967 [1]. It is an antit...
متن کاملIntravesical therapy in superficial bladder cancer.
OBJECTIVE To identify the appropriate characteristics of superficial bladder cancer that allow the physician to predict tumor behavior. METHODS We analyzed 1,745 patients with primary superficial bladder cancer with regard to disease and patient characteristics. RESULTS With the characteristics we found, the population can be described and prognostic factors can be found. Moreover, with the...
متن کاملIntravesical Therapy for Superficial Bladder Cancer
The intravesical instillation of therapeutic agents for the treatment of localized bladder cancer began in 1903 when Herring[1] summarized his experience with silver nitrate. Since then, intravesical chemotherapy and immunotherapy have emerged as effective adjuncts to endoscopic resection for superficial transitional cell carcinoma of the bladder. Although advances in the treatment of superfici...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Professional Medical Journal
سال: 2021
ISSN: 2071-7733,1024-8919
DOI: 10.29309/tpmj/2021.28.06.4968